SCHEMBL31745355

SCHEMBL31745355

COc1ccc(NC(=O)C(C)(C)Oc2ccccc2C(=O)O)cc1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.54
KMT2A Q03164 5/20 0.54
GAA P10253 2/20 0.49
POLB P06746 1/20 0.49
RAB9A P51151 6/20 0.49
NPC1 O15118 5/20 0.49
PDK1 Q15118 1/20 0.49
PDK2 Q15119 1/20 0.49
PDK3 Q15120 1/20 0.49
PDK4 Q16654 1/20 0.49
SMN1; SMN2 Q16637 4/20 0.48
MAPT P10636 3/20 0.48
METAP2 P50579 1/20 0.47
PPARA Q07869 1/20 0.46
ALDH1A1 P00352 5/20 0.46
PNLIP P16233 1/20 0.46
LMNA P02545 1/20 0.46
HTT P42858 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31745209 0.85 PDK1 (0.48) MEN1KMT2AGAARAB9ANPC1
SCHEMBL31745176 0.78 PDK1 (0.48) MEN1KMT2ARAB9ANPC1PDK1
SCHEMBL9850310 0.77 HTT (0.50) MEN1KMT2AGAARAB9ANPC1
SCHEMBL31745202 0.76 PDK1 (0.49) GAARAB9ANPC1PDK1PDK2
SCHEMBL31745365 0.75 KMT2A (0.61) MEN1KMT2AGAAPOLBRAB9A
SCHEMBL12189549 0.75 NPC1 (0.72) MEN1KMT2AGAAPOLBRAB9A
SCHEMBL24542730 0.74 PDK1 (0.55) MEN1KMT2AGAARAB9ANPC1
SCHEMBL22185077 0.74 HDAC3 (0.62) MEN1KMT2AGAAPOLBRAB9A
SCHEMBL2863787 0.73 HTT (0.69) MEN1KMT2AGAAPOLBRAB9A
SCHEMBL8042027 0.72 HSD11B1 (0.50) MEN1KMT2APDK1PDK2PDK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4667461-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON S AND GAUCHER DISEASE Children's Hospital Medical Center (US) 2025-12-24 EP disclosed
US-20250382274-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S AND GAUCHER DISEASE CHILDRENS HOSPITAL MED CT (US) 2025-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250382274-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S AND GAUCHER DISEASE GBA1, GAA, GBA2 MEN1 3321/4885KMT2A 2758/4885GAA 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.